Inogatran

Drug Profile

Inogatran

Alternative Names: H 314/27; HA 31427

Latest Information Update: 09 Mar 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Amino acids; Antiplatelets; Piperidines; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 09 Mar 2000 A re-analysis of data from the TRIM trial has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials section
  • 09 Jun 1999 A clinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics section
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top